Le Lézard
Classified in: Health, Science and technology, Business
Subjects: EARNINGS, Conference Call, Webcast, Advisory

UPDATE Pulse Biosciences Announces New Time for Third Quarter 2023 Financial Results Conference Call


Pulse Biosciences, Inc. (Nasdaq: PLSE, "the Company"), a company primarily focused on leveraging its novel and proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology for the treatment of atrial fibrillation, today announced it will now report financial results for the third quarter of 2023 before market opens on Monday, November 13, 2023. Company management will now host a corresponding conference call beginning at 9:00am PT / 12:00pm ET.

Investors interested in listening to the conference call may do so by dialing 1-877-704-4453 for domestic callers or 1-201-389-0920 for international callers. A live and recorded webcast of the event will be available at http://investors.pulsebiosciences.com/.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company's proprietary CellFX Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where CellFX nsPFA could have a profound positive impact on healthcare for both patients and providers.

Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.


These press releases may also interest you

at 09:13
The mobile app tackles the root causes of poor sleep and provides personalized lifestyle insights for users. In a recent global study, over 73% of respondents expressed a strong desire to improve sleep quality, with the primary goal being to wake up...

at 09:10
Institute of Biomedical Research Corporation is pleased to provide further details of the sale to Real American Capital Corporation of 100% ownership of the concept, business model, contacts and contracts that collectively can be used to establish...

at 09:05
Mind Medicine (MindMed) Inc. , (Cboe Canada: MMED), (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it will host a conference call and...

at 09:00
NeuroKey-3tm measures key biomarkers implicated in neurodegeneration, covering multiple aspects of Alzheimer's Disease and Dementia pathology, including neuroinflammation (IL-18), synaptic degeneration (NRGN), neurotrophic factor (BDNF), and...

at 09:00
Redefine Healthcare, a pioneer in comprehensive, patient-focused pain care, proudly announces its partnership with ReclaimAbility Pain Services (RA Pain), enhancing the range and quality of pain management services across New Jersey....

at 09:00
BioMarin Pharmaceutical Inc. today announced management is scheduled to participate in four upcoming investor conferences in March....



News published on and distributed by: